EANS-Adhoc: Marinomed Biotech AG: aws Mittelstandsfonds and Invest AG sold Marinomed shares by way of an accelerated bookbuilding for EUR 95 per share to institutional investors EAE

10/16, 8:49 AM (Source: euro adhoc)
--------------------------------------------------------------------------------
  Disclosed inside information pursuant to article 17 Market Abuse Regulation
  (MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
  The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

Capital Measures
16.10.2019

Vienna - Marinomed Biotech AG: aws Mittelstandsfonds Beteiligungs GmbH & Co. KG
and Invest Unternehmensbeteiligungs AG sold 95,000 Marinomed shares by way of an
accelerated bookbuilding for EUR 95 per share to institutional investors; upsize
option in an amount of additional 20,000 shares exercised

Vienna, 16. October 2019.

Marinomed Biotech AG (the "Company") announces that the Company was informed by
the two shareholders aws Mittelstandsfonds Beteiligungs GmbH & Co. KG ("aws
Mittelstandsfonds") and Invest Unternehmensbeteiligungs AG ("Invest AG") on 16
October 2019 that aws Mittelstandsfonds and Invest AG have sold in total 115,000
Marinomed shares from their holdings through an accelerated bookbuilding
transaction to institutional investors (the "Transaction").

The following information, put in quotation marks, is taken from the notfication
of the Company by aws Mittelstandsfonds and Invest AG:

"NOT FOR DISTRIBUTION OR PUBLICATION, EITHER DIRECTLY OR INDIRECTLY, IN THE
UNITED STATES OF AMERICA, THE UNITED KINGDOM, CANADA, JAPAN OR AUSTRALIA.

aws Mittelstandsfonds Beteiligungs GmbH & Co. KG ("aws Mittelstandsfonds") and
Invest Unternehmensbeteiligungs AG ("Invest AG") hereby announce that today, 16
October 2019, each of aws Mittelstandsfonds and Invest AG have sold 47,500
shares in Marinomed Biotech AG (ISIN ATMARINOMED6, "Marinomed shares"), thus in
aggregate 95,000 Marinomed shares, from their holdings to institutional
investors by means of an accelerated bookbuilding transaction (the "ABB"). This
amounts to 6.5% of Marionomed Biotech AG's share capital. The upsize alternative
of up to 45,000 additional Marinomed shares was exercised in an amount of 20,000
additional Marinomed shares.

The Marinomed shares were sold for EUR 95.00 each. The total sale proceeds of
the ABB for aws Mittelstandsfonds and Invest AG therefore amounts to EUR 10.93
million. Settlement of Marinomed shares placed in the ABB is scheduled for 18
October 2019.

Erste Group Bank AG acted as the sole bookrunner.

Following completion of the ABB, aws Mittelstandsfonds and Invest AG each still
hold approximately 3.2% of the share capital of Marinomed Biotech AG. For these
shares the lock-up commitment of aws Mittelstandsfonds and Invest AG, which was
entered into as part of the IPO, continues to apply.

Disclaimer:

This announcement constitutes neither an offer to buy securities nor a
solicitation of an offer to buy securities in the United States of America,
Germany, Austria or other countries. The securities are not sold or offered to
be sold in the United States of America under the rules of the US Securities Act
of 1933, as amended. The shares have already been placed.

A public offer of the securities was neither made in Austria nor in any other
jurisdiction. Any offer of shares under the ABB was made solely on the basis of
an exemption from the obligation to publish a prospectus in accordance with
Article 1 (4) of Regulation (EU) 2017/1129 of the European Parliament and of the
Council of 14 June 2017 (the "Prospectus Regulation") and was exclusively
intended for qualified investors within the meaning of Article 2 (e) of the
Prospectus Regulation."

Further inquiry note:

Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
T +43 (0)1 250 77 4460
E-Mail: eva.prieschl@marinomed.com
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Bauernmarkt 10/19, 1010 Vienna, Austria
T +43 (0) 1 504 69 87 331
E-Mail: r.mayrl@metrum.at
http://www.metrum.at

end of announcement                         euro adhoc
--------------------------------------------------------------------------------

issuer:       Marinomed Biotech AG
              Veterinärplatz 1
              A-1210 Wien
phone:        0043250774460
FAX:          0043250774493
mail:         office@marinomed.com
WWW:          www.marinomed.com
ISIN:         ATMARINOMED6, AT0000A1WD52
indexes:      
stockmarkets: Wien
language:     English

EAX0002    2019-10-16/08:49

Ad-hoc-Mitteilung übermittelt durch euro adhoc.
Für den Inhalt ist der Emittent verantwortlich.